PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

被引：0
|
作者：
Yael Babichev
Leah Kabaroff
Alessandro Datti
David Uehling
Methvin Isaac
Rima Al-awar
Michael Prakesch
Ren X. Sun
Paul C. Boutros
Rosemarie Venier
Brendan C. Dickson
Rebecca A. Gladdy
机构：
[1] Mount Sinai Hospital,Lunenfeld
[2] Lunenfeld-Tanenbaum Research Institute,Tanenbaum Research Institute
[3] University of Perugia,Sinai
[4] Ontario Institute for Cancer Research,McLaughlin Assay and Robotic Technologies Facility
[5] University of Toronto,Department of Agricultural, Food, and Environmental Sciences
[6] Ontario Institute for Cancer Research,Drug Discovery Group
[7] University of Toronto,Department of Pharmacology and Toxicology
[8] Mount Sinai Hospital,Informatics and Biocomputing Program
[9] University of Toronto,Department of Medical Biophysics
[10] University of Toronto,Department of Pathology and Laboratory Medicine
[11] Ontario Institute for Cancer Research,Department of Surgery
[12] Lunenfeld-Tanenbaum Research Institute,Institute of Medical Science
来源：
Journal of Translational Medicine | / 14卷
关键词：
Leiomyosarcoma; PI3K; mTOR; Drug discovery; Sarcoma; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
    Ouissam, Al Jarroudi
    Hind, Chibani
    Aziz, Brahmi Sami
    Said, Afqir
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [32] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    S-U Woo
    T Sangai
    A Akcakanat
    H Chen
    C Wei
    F Meric-Bernstam
    Oncogenesis, 2017, 6 : e385 - e385
  • [33] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    Woo, S-U
    Sangai, T.
    Akcakanat, A.
    Chen, H.
    Wei, C.
    Meric-Bernstam, F.
    ONCOGENESIS, 2017, 6 : e385 - e385
  • [34] MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA
    von Achenbach, Caroline
    Weller, Michael
    Kaulich, Kerstin
    Gramatzki, Dorothee
    Zacher, Angela
    Fabbro, Doriano
    Reifenberger, Guido
    Szabo, Emese
    NEURO-ONCOLOGY, 2018, 20 : 48 - 48
  • [35] Quantification of PI3K/AKT/mTOR pathway inhibition is predictive of biological response
    Van Brussel, A.
    Wesseling-Rozendaal, Y.
    Den Biezen, E.
    Neerken, S.
    van de Wiel, P.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S81 - S81
  • [36] Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
    Sathe, Anuja
    Chalaud, Geraldine
    Oppolzer, Immanuel
    Wong, Kit Yeng
    von Busch, Margarita
    Schmid, Sebastian C.
    Tong, Zhichao
    Retz, Margitta
    Gschwend, Juergen E.
    Schulz, Wolfgang A.
    Nawroth, Roman
    PLOS ONE, 2018, 13 (01):
  • [37] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [38] Oncogenic Roles of the PI3K/AKT/mTOR Axis
    Aoki, Masahiro
    Fujishita, Teruaki
    VIRUSES, GENES, AND CANCER, 2017, 407 : 153 - 189
  • [39] PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors
    Wolin, Edward M.
    CANCER LETTERS, 2013, 335 (01) : 1 - 8
  • [40] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
12345